Quarterly report [Sections 13 or 15(d)]

Fair Value Measurements - Narrative (Details)

v3.25.1
Fair Value Measurements - Narrative (Details)
 3 Months Ended
Mar. 28, 2024
USD ($)
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Change in fair value   $ 79,300,000        
Warrant liability | Private Placement            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Private placement warrants outstanding   0        
Warrant liability   0        
Series C Preferred Stock | Private Placement            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Net proceeds $ 115,600,000 115,600,000        
Level 3            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Initial valuation of warrant liability     $ 194,901,000      
Fair value   8,100,000 200,571,000   $ 8,480,000 $ 5,550,000
Change in fair value   (380,000) 120,000      
AVTX-501            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Maximum aggregate milestone payment       $ 20,000,000    
Derivative liability   0        
AVTX-007            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Initial valuation of warrant liability   400,000        
AVTX-007 | Milestone One            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Maximum aggregate milestone payment       6,250,000    
AVTX-007 | Milestone Two            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Maximum aggregate milestone payment       67,500,000    
AVTX-611            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Maximum aggregate milestone payment       20,000,000    
Derivative liability | Level 3            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Initial valuation of warrant liability     0      
Fair value   8,100,000 5,670,000   $ 8,480,000 5,550,000
Change in fair value   (380,000) 120,000      
Derivative liability | AVTX-501            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Initial valuation of warrant liability       $ 3,500,000    
Derivative liability | AVTX-501 | Measurement Input, Probability Of Success            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Derivative liability, measurement input       0.01    
Derivative liability | AVTX-007            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Initial valuation of warrant liability       $ 1,300,000    
Fair value   8,100,000        
Derivative liability | AVTX-007 | Measurement Input, Probability Of Success            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Derivative liability, measurement input       0.17    
Derivative liability | AVTX-007 | Measurement Input, Sales Forecast Peak            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Net proceeds from the sale       $ 1,800,000,000    
Derivative liability | AVTX-007 | Measurement Input, Expected Term            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Derivative liability, measurement input, term       5 years 9 months 18 days    
Derivative liability | AVTX-501 And AVTX-007            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Initial valuation of warrant liability       $ 4,800,000    
Changes in fair value, gain (loss)   400,000        
Warrant liability | Level 3            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Initial valuation of warrant liability   $ 194,900,000 194,901,000      
Fair value     194,901,000     $ 0
Change in fair value     $ 0      
ES Therapeutics, LLC | Derivative liability            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Initial valuation of warrant liability       $ 5,000,000